Perinatal Infection Screening and Prophylaxis Guidelines
All pregnant women should undergo universal screening for Group B Streptococcus (GBS) at 35-37 weeks gestation with rectovaginal culture and receive intrapartum antibiotic prophylaxis if positive, plus universal syphilis screening at the first prenatal visit. 1, 2
Group B Streptococcus (GBS) Prevention
Screening Protocol
- Perform universal antenatal GBS screening at 35-37 weeks gestation using rectovaginal swab culture 1
- This strategy has achieved an 80% reduction in early-onset GBS disease since implementation 1, 3
- Do NOT treat GBS colonization during pregnancy—only provide intrapartum prophylaxis 1
Intrapartum Antibiotic Prophylaxis (IAP) Indications
Administer IAP to women with:
- Positive GBS screening culture at 35-37 weeks
- GBS bacteriuria at any time during current pregnancy
- Previous infant with invasive GBS disease
- Unknown GBS status with risk factors: preterm labor <37 weeks, rupture of membranes ≥18 hours, or intrapartum fever ≥100.4°F (38°C) 1
IAP Administration
- First-line: Penicillin G intravenously
- Penicillin allergy (low anaphylaxis risk): Cefazolin
- Penicillin allergy (high anaphylaxis risk): Requires susceptibility testing; use clindamycin if susceptible, vancomycin if resistant 1
- Timing: Administer at least 4 hours before delivery for maximum effectiveness (91% efficacy in term infants, 86% in preterm when adequate duration achieved) 3
No IAP Required
- GBS-positive women undergoing planned cesarean delivery with intact membranes 1
Common Pitfall: The 2010 CDC guidelines updated penicillin allergy management and preterm labor algorithms—ensure you're following current protocols, not the outdated 2002 version 1
Syphilis Screening
Universal Screening Protocol
Screen ALL pregnant women for syphilis with nontreponemal testing (RPR or VDRL) at the first prenatal visit 2
High-Risk Populations Requiring Additional Screening
Repeat testing at 28 weeks gestation AND at delivery for:
- Women in high-prevalence areas (southern United States, certain metropolitan areas)
- Uninsured women or those living in poverty
- Sex workers or illicit drug users
- Hispanic and African-American populations (higher prevalence)
- Women with other sexually transmitted diseases
- After exposure to infected partner 2
Diagnostic Approach
- Initial screening: Nontreponemal test (VDRL or RPR)
- Confirmation: Fluorescent treponemal antibody absorbed test or Treponema pallidum particle agglutination (TPPA) test 2
- Follow-up: Use the same nontreponemal test for serial monitoring to ensure comparable results 2
Treatment
- Only treatment: Parenteral benzathine penicillin G
- Penicillin allergy: Evaluate allergy, then desensitize and treat with penicillin—no acceptable alternatives exist in pregnancy 2
Critical Point: Most states legally mandate syphilis screening during pregnancy, with many requiring screening at delivery 2
Other Perinatal Infections
Additional Recommended Screening
The USPSTF has established recommendations for screening:
- Hepatitis B
- HIV
- Chlamydia
- Gonorrhea 2
Emerging Considerations
Recent evidence suggests:
- CMV screening: Remains controversial; most guidelines (SMFM, RCOG, RANZCOG) recommend against universal screening, though ECCI recommends routine screening up to 16 weeks in high-risk populations 4
- Rubella screening: Universal screening practices are being reconsidered as epidemiology changes 5
Implementation Challenges
Major compliance issue identified: 30% of women positive for GBS receive inadequate IAP (less than 4 hours before delivery) despite spending more than 60 minutes in hospital before birth 6. This represents a significant missed opportunity for prevention that requires systematic improvement in labor and delivery protocols.
The evidence strongly supports that when these screening and prophylaxis protocols are properly implemented, they substantially reduce neonatal morbidity and mortality from preventable perinatal infections 1, 3.